Use of bisphosphonates in chronic kidney disease;Uso de bifosfonatos en la enfermedad renal crónica

Nefrologia

Volumn 30, Issue 3, 2010, Pages 288-297

  Torregrosa, J V ^a   Ramos, A M ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Bisphosphonates; Chronic kidney disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BIOAVAILABILITY; BIOPSY; BONE; BONE DENSITY; BONE NECROSIS; BONE REMODELING; CALCINOSIS; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CHRONIC DISEASE; CLASSIFICATION; DRUG EFFECT; HUMAN; JAW DISEASE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; METABOLIC CLEARANCE RATE; METABOLISM; OSTEOPOROSIS; PATHOLOGY; RENAL OSTEODYSTROPHY; REVIEW; VASCULAR DISEASE;

BIOLOGICAL AVAILABILITY; BIOPSY; BONE AND BONES; BONE DENSITY; BONE REMODELING; CALCINOSIS; CALCIPHYLAXIS; CHRONIC DISEASE; DIPHOSPHONATES; HUMANS; JAW DISEASES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; METABOLIC CLEARANCE RATE; OSTEONECROSIS; OSTEOPOROSIS; RENAL OSTEODYSTROPHY; VASCULAR DISEASES;

EID: 77954627003     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Mar.10320     Document Type: Review

References (54)

1. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222-30.
2. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int 2008;19:733-59.
3. Courtney AE, Maxwell A P. Chronic kidney disease and bisphosphonate treatment: are prescribing guidelines unnecessarily restrictive? Postgrad Med J 2009;85:327-30.
4. Lühe A, Künkele K P, Haiker M, Schad K, Zihlmann C, Bauss F, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate synthase in the kidney: implications for renal safety. Toxicology 2008;22:899-909.
5. Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration. Toxicology 2003;191:159-67.
6. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008;74:1385-93.
7. Bergner R, Diel IJ, Henrich D, Hoffman M, Uppenkamp M. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006;29:534-40.
8. Hernández M V, Peris P, Monegal A, Reyes R, Muxí A, Gifré L, et al. Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis. Am J Med Sci 2010;339:225-9.
9. Bonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008;74:641-8.
10. Diel IJ, Weide R, Köppler H, Neary M, Duh MS. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer 2009;17:719-25.
11. Body JJ, Pfister T, Bausss F. Preclinical perspectives on biphosphonate renal safety. The Oncologist 2005;10:3-7.
12. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004;65:634-41.
13. Shreedhara M, Fenves AZ, Benavides D, Stone MJ. Reversibility of pamidronate-associated glomeruloesclerosis. Proc Bayl Univ Med Cent 2007;20:249-53.
14. Nagahama M, Sica DA. Pamidronate-induced kidney injury in a patient with metastatic breast cancer. Am J Med Sci 2009;338:225-8.
15. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zole-dronate. Kidney Int 2003;64:281-9.
16. Bergner R, Henrich DM, Hoffmann M, Honocker A, Mikus G, Nauth B, et al. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 2007;47:942-50.
17. Miura N, Mizuno N, Aoyama R, Kitagawa W, Yamada H, Nishikawa K, et al. Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis. Clin Exp Nephrol 2009;13:85-8.
18. Ersoy FF. Osteoporosis in the elderly with chronic kidney disease. Int Urol Nephrol 2007;39:321-31.
19. Miller PD, Roux C, Boonen S, Barton I P, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005;20:2105-15.
20. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007;22:503-8.
21. Jacksob GH. Renal safety of Ibandronate. The Oncologist 2005;10:14-8.
22. Henrich D, Hoffman M, Uppenkamp M, Bergner R. Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: case reports. Acta Haematol 2006;116:165-72.
23. Von Moos R, Caspar CB, Thürlimann B, Angst R, Inauen R, Greil R, et al. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. Ann Oncol 2008;19:1266-70.
24. Chantzichristos D, Andréasson B, Johansson P. Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients. The-rap Clin Risk Manag 2008;4:1371-4.
25. Sierra F, Román A, Barreda C, Moleón M, Pastor J, Navas A. Influencia del tiempo de perfusión de pamidronato sobre la función renal en pacientes con mieloma múltiple. Farm Hosp 2010;34:23-6.
26. Buttazzoni M, Rosa Díez GJ, Jager V, Crucelegui MS, Algranati SL, Plantalech L. Elimination and clearance of pamidronate by haemodialysis. Nephrology 2006; 11:197-200.
27. Ala-Houhala I, Saha H, Liukko-Sipi S, Ylitalo P, Pasternack A. Pharmacokinetics of clodronate in haemodialysis patients. Nephrol Dial Transplant 1999;14:699-705.
28. Beigel AE, Rienhoff E, Olbricht CJ. Removal of clodronate by haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant 1995;10:2266-8.
29. Bergner R, Dill K, Boerner D, Uppenkamp M. Elimination of intravenously administered ibandronate in patients on haemodialysis: A monocentre open study. Nephrol Dial Transplant 2002;17:1281-5.
30. Henrich DM, Hoffman M, Uppenkamp M, Bergner R. Tolerability on dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series. Onkologie 2009;32:482-6.
31. Saha H. Skeletal deposition of clodronate is related to parathyroid function and bone turnover in dialysis patients. Clin Nephrol 2002;58:47-53.
32. Torregrosa JV, Fuster D, Monegal A, Gentil MA, Bravo J, Guirado L, et al. Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant. Osteoporos Int 2010. En prensa.
33. Torregrosa JV, Fuster D, Gentil MA, Marcen R, Guirado L, Zarraga S, et al. Open-label trial: effect of weekly risedronate inmediately after transplantation in kidney recipients. Transplantation 2010. En prensa.
34. Ste-Marie LG, Sod E, Johnson T, Chines A. Five years of treatment with risedronate an its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:469-76.
35. Bergner R, Henrich D, Hoffmann M, Schmidt-Gayk H, Lenz T, Upperkamp M. Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol 2008;21:510-5.
36. Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 2007;20:186-90.
37. Torregrosa J V, Moreno A, Mas M, Ybarra J, Fuster D. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int 2003;85:88-90.
38. Wetmore JB, Benet LZ, Kleinstuck D, Frassetto L. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology 2005;10:393-9.
39. Price PA, Omid N, Than TN, Williamson MK. The aminobisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resoption. Calcif Tissue Int 2002;71:356-63.
40. Monney P, Nguyen Q V, Perroud H, Descombres E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004;19:2130-2.
41. Shiraishi N, Kitamura K, Miyoshi T, Adachi M, Kohda Y, Nonoguchi H, et al. Succesful treatment of a patients with severe calcifil uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006;48:151-4.
42. Schliep S, Schuler G, Kiesewetter F. Sucessful treatment of calciphylaxis with pamidronate. Eur J Dermatol 2008;18:554-6.
43. Czosnowski LM, Hudson JQ, Canada RB. Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient. Am J Med Sci 2009;337:300-1.
44. Fiore CE, Pennisi P, Pulvirenti I, Francucci CM. Bisphosphonates and atherosclerosis. J Endocrinol Invest 2009;32:38-43.
45. Lomashvili KA, Khawandi W, O'Neil WC. Reduced plasma pyrophos-phate levels in hemodialysis patients. J Am Soc Nephrol 2005;16:2495-500.
46. Hill JA, Goldin JG, Gjerston D, Emerick AM, Greaser LD, Yoon HC, et al. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol 2002;9:1148-52.
47. Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporosis Int 2005;16:184-90.
48. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004;44:680-8.
49. Hashiba H, Aizawa S, Tamura K, Kogo H. Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 2006;10:59-64.
50. Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T. Effect ofetidronic acid on arterial calcification in dialysis patients. Clin Drug Invest 2006;26:215-22.
51. Sung EC, Chan SM, Sakurai K, Chung E. Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec Care Dentist 2002;22:142-6.
52. Merigo E, Manfredi M, Meleti M, Guidotti R, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 2006;77:109-17.
53. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer 2005;104:83-93.
54. Khosla S. Bisphosphonate associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.